Kaku Saito
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Strategic Integration of Companion Diagnostics in Precision Oncology: Key Factors, Drug Development Timelines, and Regulatory Insights from U.S. FDA Approvals.
Journal: Therapeutic innovation & regulatory science
Published: September 26, 2025
Bridging Gaps in Oncology: Comparative Analysis of Development and Approval Pathways for Anticancer Drugs and Companion Diagnostic in the United States and Japan.
Journal: Clinical and translational science
Published: December 20, 2024
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Journal: Nature medicine
Published: November 09, 2023
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 15, 2022
Pharmacological and clinical study results of trastuzumab deruxtecan (T-DXd, ENHERTU®)
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: January 04, 2021
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Journal: The New England journal of medicine
Published: May 30, 2020
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Journal: The Lancet. Oncology
Published: October 12, 2018
First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers.
Journal: Cancer chemotherapy and pharmacology
Published: August 02, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026